Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;34(4):751-771.
doi: 10.1016/j.idc.2020.08.004.

Resistance in Vancomycin-Resistant Enterococci

William R Miller  1 , Barbara E Murray  2 , Louis B Rice  3 , Cesar A Arias  4
Affiliations
Review

Resistance in Vancomycin-Resistant Enterococci

William R Miller et al. Infect Dis Clin North Am. 2020 Dec.

Abstract

Serious infections owing to vancomycin-resistant enterococci have historically proven to be difficult clinical cases, requiring combination therapy and management of treatment-related toxicity. Despite the introduction of new antibiotics with activity against vancomycin-resistant enterococci to the therapeutic armamentarium, significant challenges remain. An understanding of the factors driving the emergence of resistance in vancomycin-resistant enterococci, the dynamics of gastrointestinal colonization and microbiota-mediated colonization resistance, and the mechanisms of resistance to the currently available therapeutics will permit clinicians to be better prepared to tackle these challenging hospital-associated pathogens.

Keywords: Colonization resistance; Mechanisms of resistance; VRE; VRE colonization; Vancomycin resistant enterococcus.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr W.R. Miller has received grants from Merck and Entasis Therapeutics, and honoraria from Achaogen and Shionogi. Dr B.E. Murray has received grant support from Theravance Biopharma, Paratek, and Cubist/Merck, and has served as consultant for Paratek. Dr L.B. Rice has served on data safety monitoring boards for Zavante Pharmaceuticals and VenatoRx Pharmaceuticals. Dr C.A. Arias has received grant support from Merck, MeMed Diagnostics, and Entasis Therapeutics.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. García-Solache M, Rice LB. 2019. The enterococcus: A model of adaptability to its environment. Clin Microbiol Rev 32:1–28. - PMC - PubMed
    1. Miller WR, Arias CA, Murray BE. 2020. Enterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species, p. 2492–2504. In Bennett JE, Dolin R, Blaser MJ (eds.), Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases 9th Ed., 9th ed. Elsevier, Philidelphia.
    1. Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, Pollock D, See I, Soe MM, Walters MS, Dudeck MA. 2020. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol 41:1–18. - PMC - PubMed
    1. Schleifer KH, Kilpper-Bälz R. 1984. Transfer of Streptococcus faecalis and Streptococcus faecium to the Genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov. Int J Syst Evol Microbiol 34:31–34.
    1. Williamson R, Calderwood SB, Moellering RC, Tomasz A. 1983. Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol 129:813–22. - PubMed

Publication types

MeSH terms

Substances